What the label says
Oral Wegovy does not have a simple one-page “avoid” list
The current DailyMed Wegovy set, revised June 2026, includes once-daily semaglutide tablets and injection presentations. Its drug-interaction section focuses on insulin or insulin secretagogues such as sulfonylureas and on oral medicines whose absorption or monitoring could be affected. That is different from saying every oral medicine has a proven clinically important interaction. A safe review considers the exact medicine, its therapeutic window, timing requirements, laboratory monitoring, glucose effects, stomach symptoms, and the patient’s ability to follow the tablet routine.
- Bring the pharmacy label or medication-list record rather than relying on categories such as “thyroid pill,” “diabetes pill,” or “vitamins.”
- Include as-needed medicines, injections, patches, liquids, supplements, protein or electrolyte products, and recently stopped prescriptions.
- Ask whether the concern is a measured drug interaction, administration-timing conflict, low-blood-sugar overlap, dehydration risk, side-effect overlap, or duplicate GLP-1 therapy.
Thyroid medicine
Levothyroxine exposure increased in a semaglutide-tablet interaction study
The June 2026 Wegovy label reports that levothyroxine exposure increased 33% in a drug-interaction study with the semaglutide tablet. Both products can also have strict administration instructions. This does not establish one universal clock schedule or mean thyroid medicine should be stopped. The prescriber or pharmacist should review the exact thyroid product, laboratory history, symptoms, current timing, and whether thyroid testing or a schedule adjustment is appropriate after starting or changing oral Wegovy.
- Do not take levothyroxine at the same moment as the Wegovy tablet unless the prescriber or pharmacist specifically directs that plan.
- Do not change thyroid-medicine strength or alternate days based on a social-media spacing rule or a single thyroid result.
- Report symptoms that could reflect a thyroid-treatment change, but use laboratory and clinical review rather than assuming every symptom is a drug interaction.
Diabetes medicines
Insulin and sulfonylureas can increase low-blood-sugar risk
Wegovy lowers blood glucose. Its label says hypoglycemia risk is increased when it is used with insulin or an insulin secretagogue such as a sulfonylurea. The label tells prescribers to consider whether those medicines need adjustment when Wegovy is initiated; that is a clinician decision, not permission for a patient to reduce insulin independently. Glucose history, the exact diabetes medicines, food intake, nausea or vomiting, kidney function, and the monitoring plan all matter.
- Name the insulin type and schedule and the exact sulfonylurea or other glucose-lowering medicines rather than reporting only “diabetes medication.”
- Ask who will review glucose readings, continuous-glucose-monitor alerts, low intake, vomiting, dose changes, and low-blood-sugar symptoms.
- Severe confusion, seizure, fainting, inability to safely treat a low, or repeated low readings needs prompt medical guidance under the documented diabetes plan.
Oral absorption and timing
Delayed stomach emptying and the 30-minute routine can affect other pills
Wegovy delays gastric emptying and therefore has the potential to affect absorption of oral medicines. The label recommends monitoring oral medicines used with Wegovy and considering increased clinical or laboratory monitoring for medicines with a narrow therapeutic index or those that already require clinical monitoring. Separately, the tablet must be taken in the morning on an empty stomach with plain water only—up to 4 ounces—and followed by at least 30 minutes before food, another beverage, or another oral medicine. Those are related but distinct issues.
- Ask about anticoagulants, antiseizure medicines, transplant or immune medicines, thyroid products, heart medicines, and any drug whose label requires precise timing or routine blood tests; the pharmacist should assess the actual product.
- Minerals, vitamins, antacids, reflux products, iron, calcium, and supplements can have their own timing rules even when no Wegovy-specific interaction has been proven.
- Do not shorten the wait, take several strict-timing medicines together, or move an important prescription to bedtime without product-specific guidance.
Side-effect and safety overlap
Some medicine combinations matter because symptoms and risks can compound
A medication review should look beyond formal pharmacokinetic interactions. Diuretics or other medicines that affect fluid balance can become more important if nausea, vomiting, diarrhea, or low intake causes dehydration. Blood-pressure medicines may need symptom and reading review when dizziness or volume loss occurs. Medicines that already affect appetite, stomach emptying, constipation, or nausea can complicate tolerability. These are reasons for coordinated monitoring—not reasons to automatically stop treatment.
- Record vomiting, diarrhea, constipation, abdominal pain, fluid intake, urine output, dizziness, blood pressure, glucose when relevant, and the timing of other medicines.
- Repeated vomiting, inability to keep fluids down, very low urine output, fainting, severe persistent abdominal pain, allergic symptoms, or sudden vision changes needs prompt medical guidance.
- Tell the procedure and anesthesia team about Wegovy because delayed stomach emptying is relevant around general anesthesia or deep sedation; follow an individualized plan rather than an online hold schedule.
Duplicate therapy and seller claims
Do not stack oral Wegovy with another semaglutide or GLP-1 product
Wegovy tablets contain semaglutide. Using them with Wegovy injection, Ozempic, Rybelsus, compounded semaglutide, tirzepatide, Foundayo, or another GLP-1 pathway product is not a casual supplement stack. A clinician-directed switch is different from overlapping products. Compounded medications are not FDA-approved finished drug products or generic Wegovy tablets, and a seller should not bypass medication reconciliation because a product is described as “low dose,” “natural,” or “personalized.”
- Reject no-prescription checkout, loose tablets, research-use material, hidden pharmacy sourcing, and sellers that recommend overlapping GLP-1 products.
- Reject universal interaction checkers that never ask for the exact product, dose form, medical history, laboratory monitoring, or pharmacy label.
- If treatment is unaffordable, unavailable, or hard to schedule, discuss lawful alternatives with a licensed clinician instead of mixing products or skipping another prescription.